RhoVac’s attending events in August and September 2019
RhoVac AB ("RhoVac") will attend shareholder meetings in Stockholm and international partnering meetings during August and September 2019.
Anders Månsson (vice deputy & CBO) will present the company to shareholders at FS Market, August 27th, Hotel Anglais, Stockholm.
2nd LSX Nordic Congress, 28 - 29 August, NASDAQ Stockholm, Stockholm, Sweden
Nordic Life Science Days, 10-12 September, Malmö/Copenhagen, Sweden/Denmark.
19th Annual Biotech in Europe Forum, 25-26 September, Basel, Switzerland.
ESMO, 27th September – 1st October, Barcelona, Spain.
Swedish-French Life Science Days, 1– 2nd October, Paris, France.
For more information, please contact:
Anders Ljungqvist – CEO, RhoVac AB
Phone: +46 73-751 72 78
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed clinical phase I/II and clinical phase IIb development has been initiated. RhoVac has its headquarters at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com